← back to search

Alan L. Leggett

Dana-Farber Cancer Institute · US
Area of research
Molecular Biology · Oncology
Research interest
Research interests include Protein Degradation and Inhibitors, Ubiquitin and proteasome pathways, DNA Repair Mechanisms, and Cancer-related Molecular Pathways.
h-index
13
citations
2,709
works
20
NIH funding
primary concept
email

Recent publications

Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Nature Communications 2020cited by 308position: middledoi
Discovery of a selective inhibitor of doublecortin like kinase 1
Nature Chemical Biology 2020cited by 113position: middledoi
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Cancer Cell 2019cited by 222position: middledoi
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype
Cell chemical biology 2019cited by 163position: middledoi
The dTAG system for immediate and target-specific protein degradation
Nature Chemical Biology 2018cited by 1,147position: middledoi
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma
Cancer Cell 2018cited by 169position: middledoi
Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13
eLife 2018cited by 165position: middledoi
SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform
Cell chemical biology 2018cited by 128position: middledoi
Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression
Cancer Discovery 2017cited by 141position: middledoi
Inflammasome Modulation by Chemotherapeutics in Malignant Mesothelioma
PLoS ONE 2015cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Nathanael S. Gray · Stanford University6 papers (2018–2020)Tinghu Zhang · Stanford University4 papers (2018–2019)Nicholas Kwiatkowski · Woomera Therapeutics3 papers (2018–2019)Behnam Nabet · Fred Hutch Cancer Center3 papers (2018–2020)Jun Qi · Harvard University2 papers (2018–2018)Dennis L. Buckley · Novartis (China)2 papers (2018–2020)Scott B. Ficarro · Harvard University2 papers (2018–2019)Amy Saur Conway · Dana-Farber/Boston Children's Cancer and Blood Disorders Center2 papers (2018–2020)James E. Bradner · Novartis (China)2 papers (2018–2020)Yanke Liang · Massachusetts Institute of Technology2 papers (2018–2019)Kimberly Stegmaier · Harvard University2 papers (2018–2020)Jarrod A. Marto · Harvard University2 papers (2018–2019)Charles Y. Lin · South Texas Accelerated Research Therapeutics2 papers (2018–2019)Amanda L. Robichaud · AstraZeneca (United States)1 papers (2020–2020)Shan Zhou · Harbin Medical University1 papers (2018–2018)Ursula A. Matulonis · Harvard University1 papers (2018–2018)Cyril H. Benes · Virginia Commonwealth University1 papers (2018–2018)Arti Shukla · University of Vermont1 papers (2015–2015)Joyce F. Liu · Harvard University1 papers (2018–2018)Sangeetha Palakurthi · Io Therapeutics (United States)1 papers (2018–2018)